ENG
RUS
ENG
RUS
Company
Fusion Pharma company was founded in 2010 by a group of scientists with expertise in the field of medicinal chemistry and computer-aided drug design and private investors from the pharmaceutical industry. The company's efforts were focused on the development of an innovative drug for the treatment of resistant forms of chronic myelogenous leukemia (CML), including its T315I mutant version. Currently, the drug candidate PF-114, an inhibitor of the 3rd generation of the oncogene BCR-ABL, is in the phase 1 clinical trials in the target group of patients. The company plans to conduct an international multicenter pivotal clinical trial. Since 2011, the company is a resident of the Skolkovo Innovation Center and is conducting its research with the broad support of the Skolkovo Foundation.
Team
  • Ghermes Chilov, PhD
    General director
    Ghermes received a diploma and a PhD degree in chemistry from the Lomonosov Moscow State University. Additional education in the field of innovation management at the Economics Faculty of Moscow State University, Schulich business school in Toronto, business school of the Karolinska Institute of Technology, Stockholm. The founder of MolTech company, which developed the software Lead Finder for the drug design. More than 10 years of experience in developing new drugs.
  • Veronika Shulgina, MD., PhD
    Director of medical strategy and clinical studies
    Veronika graduated from Chelyabinsk State Medical Academy as MD, and completed residency in Endocrinology and Cardiology at First Moscow State Medical University named after I.M. Sechenov. Veronika made her thesis in National Endocrine Center. She experienced from a number of contract clinical organizations and also took her leading positions at Medical Affairs in Novo Nordisk, Novartis and Shire.
  • Ilya Titov
    Chief medicinal chemistry
    Ilya received his diploma in chemistry from the Higher Chemical College of the Russian Academy of Sciences. Collaborated as a synthetic chemist with Abbott, ImClone, Asinex. Author of several patents for new classes of biologically active compounds, co-author of the drug candidate PF-114.
  • Fedor Novikov, PhD
    Project leader
    Fedor received his diploma and a PhD degree from the chemical faculty of the Lomonosov Moscow State University. Co-author of the Lead Finder software for the drug design. More than 10 years of experience in developing new drugs.
  • Anastasia Kurnosova, CPA
    Chief accountant
    Anastasia is a CPA certified accountant, she received a diploma in economics from the Moscow University of Environmental Engineering and has been with the company since its inception.
  • Ilya Mikhailov
    Medical advisor
    Ilya studies medicine at the Faculty of Fundamental Medicine of Moscow State University, MV Lomonosov. Ilya is fascinated by the search for answers in the scientific literature on medical issues that arise during the drug development and clinical studies.
Supervisory board
  • Oleg Kedrovskiy
    Board Chairman
    Oleg Kedrovskiy is a graduate of the Moscow State Institute of International Relations, a financier, a significant participant in the Russian pharmaceutical market, chairman of the board of directors of Valenta Pharmaceuticals, one of the largest Russian pharmaceutical companies.
  • Leysan Shaidullina, MD, MBA
    Board member
    Leysan graduated from the Kazan State Medical University. Has an MBA degree in innovation and technology management, obtained at the Academy of National Economy under the Government of the Russian Federation. Leysan has extensive experience in venture investment in biotech companies, being the managing director for investment activities in Rusnano venture capital.
  • Vladimir Nebol'sin, PhD
    Board member
    Vladimir Nebol'sin received his diploma and a PhD degree from the Moscow Institute of Fine Chemical Technology. A successful entrepreneur in Russian pharmaceuticals, a developer of Ingavirin, the leader in antiviral sales in Russia. The founder of the company Myelo conducting international development of a medicinal product in oncology and oncohematology.
  • Ghermes Chilov, PhD
    Board member
    Ghermes Chilov is a member of the Supervisory Board of the company as CEO and developer of PF-114.
Advisory board
  • Michele Baccarani, Prof., MD
    S. Orsola-Malpighi University Hospital, Bologna, Italy
    Prof. Baccarani is a founder of European Leukemia Net, #1 leukemia society in Europe; leading co-author of European CML treatment guidelines.
  • Robert Gale, Prof., MD
    Imperial College London, London, UK
    Prof. Gail sequenced the BCR-ABL oncogene, opening the way to targeted CML therapy. He participated in the rescue of irradiated patients after the explosion at the Chernobyl nuclear power plant. Has a rich experience in conducting clinical trials by pharmaceutical companies.
  • Michael Deininger, Prof., MD
    University of Utah, Salt Lake City, USA
    Prof. Deininger is a leading CML biologist, clinician, co-author of NCCN guidelines for CML treatment.
  • Andreas Hochhaus, Prof., MD
    UniversitätsTumor Centrum Jena, Jena, Germany
    Prof. Hochhaus has been involved in the CML Studies I-IV for more than 19 years. His special interests are the molecular monitoring of minimal residual disease and mechanisms of resistance in CML, and targeted therapy in a variety of neoplasms.
  • Timothy Hughes, Prof., MD
    Royal Adelaide Hospital, Adelaide, Australia
    Prof. Hughes clinical interests include chronic leukaemias and myeloproliferative disorders. His research interests are in molecular monitoring for leukaemias, resistance to targeted therapies and the development of assays to predict response and resistance to targeted agents.
  • Shinya Kimura, Prof., MD
    Saga University, Saga, Japan
    Professor Kimura is an active participant in clinical trials of drugs against leukemia and CML in Japan, a member of the Orphan Drugs Committee of the Ministry of Health, Labor and Welfare of Japan.
  • Jorge Cortes, Prof., MD
    University of Texas MD Anderson Cancer Center, Houston, USA
    Prof. Cortez — one of the world leaders in the field of therapy for CML, he made a significant contribution to the clinical development of all currently approved targeted CML drugs.
  • Oliver Ottmann Prof., MD
    Cardiff University, Cardiff, UK
    Prof. Ottmann has led the development of novel drugs and highly targeted approaches, including immunotherapies and molecularly directed agents. His clinical and research efforts have been focused on providing therapy for patients suffering from treatment-resistant or refractory leukemia, with a special emphasis on acute lymphoblastic leukaemia and on interrogating the mechanisms of resistance to targeted therapy.
  • Giuseppe Saglio, Prof., MD
    University of Turin, Turin, Italy
    Area of interest prof. Saglio lies in conducting clinical studies and molecular diagnostics in CML and other myeloproliferative diseases.
  • Anna Turkina, Prof., MD
    Hematologic Scientific Center, Moscow, Russia
    Prof. Turkina has vast clinical experience in the therapy of myeloproliferative diseases, and in particular CML. She has served as principal investigator on numerous national and international clinical studies of many novel agents.
  • Meg Valnoski, MBA
    Theradex Ltd, USA
    Meg Valnoski is the head of the contract clinical organization Teradex, specializing in conducting clinical research in the field of oncology. Has more than 20 years of experience in regulatory matters with the US Food and Drug Administration.
  • Patrick Gearing, PhD
    Ridge Biotechnology Consulting, USA
    Patrick Gearing is a specialist in the field of pharmaceutical development of low-molecular and biologics drugs, he worked in leading positions in large biotechnological and pharmaceutical companies.
Made on
Tilda